Form 4 for CRSP CRISPR Therapeutics AG
Accepted 2024-12-27 00:00:00 ET · period of report 2024-12-24 · accession 0000950170-24-140846 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-27 | 2024-12-24 | CRSP | Kulkarni Samarth | CEO, Dir | M - OptEx | $16.21 | +13.8K | 195.3K | +8% | +$222.9K |
| D | 2024-12-27 | 2024-12-24 | CRSP | Kulkarni Samarth | CEO, Dir | M - OptEx | $0.00 | -13.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2024-12-24 | M | A | 13,751 | $16.21 | 195,291 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-12-24 | M | D | 13,751 | $0.00 | 0 | D | $16.21 · — to 2027-05-03 | 13,751 Common Shares | (F1) This option was granted on May 3, 2017 with respect to 100,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning May 31, 2017. |